文献速递角膜与眼表疾病

源自免疫防御蛋白CAP37的抗菌肽抑制S100A9对TLR4的激活

Antimicrobial Peptides Derived from the Immune Defense Protein CAP37 Inhibit TLR4 Activation by S100A9.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2020-01-01

本研究用TriCEPS配体-受体糖捕获法在人角膜上皮细胞系hTCEpi上鉴定CAP37结合伙伴,并用ELISA和报告细胞系验证。发现CAP37及四种衍生肽均以高亲和力结合S100A9,且CAP37和四种肽均能抑制S100A9对TLR4的激活。该机制可能限制角膜损伤炎症反应并促进再上皮化。

要点

  • CAP37及四种衍生肽以高亲和力结合S100A9。
  • CAP37和四种肽均抑制S100A9激活TLR4。
  • 该机制可能限制角膜损伤炎症并促进再上皮化。

核心结论

  • CAP37及其衍生抗菌肽通过结合S100A9并抑制S100A9对TLR4的激活发挥作用,可能限制角膜损伤炎症反应并利于角膜再上皮化。

研究设计与样本

  • 采用TriCEPS配体-受体糖捕获法在活人角膜上皮细胞系hTCEpi上鉴定CAP37结合伙伴,用ELISA确认结合,用报告细胞系测量TLR4激活。

主要发现

  • CAP37及四种衍生肽(覆盖CAP37两个区域)以高亲和力结合S100A9。
  • CAP37和S100A9结合肽可直接与TLR4相互作用,CAP37和一种肽部分激活TLR4,另三种肽不激活TLR4。
  • CAP37和所有四种肽均能抑制S100A9对TLR4的激活。

临床怎么用

  • 提示CAP37衍生抗菌肽可能用于角膜擦伤后限制炎症反应并促进再上皮化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Corneal abrasion is a common eye injury, and its resolution can be seriously complicated by bacterial infection. We showed that topical application of the cationic antimicrobial protein of 37 kDa (CAP37) promotes corneal re-epithelialization in mice, and peptides derived from CAP37 can recapitulate the antibacterial and wound-healing effects of the full-length protein. The current study was designed to identify the molecular mechanisms mediating the wound-healing effect of CAP37 and derived bioactive peptides. METHODS: We used a TriCEPS-based, ligand-receptor glycocapture method to identify the binding partners of CAP37 on live human corneal epithelial cells using the hTCEpi cell line. We used an ELISA method to confirm binding with identified partners and test the binding with CAP37-derived peptides. We used a reporter cell line to measure activation of the identified membrane receptor by CAP37 and derived peptides. RESULTS: We pulled down S100 calcium-binding protein A9 (S100A9) as a binding partner of CAP37 and found that CAP37 and four derived peptides encompassing two regions of CAP37 bind S100A9 with high affinities. We found that CAP37 and the S100A9-binding peptides could also directly interact with the Toll-like receptor 4 (TLR4), a known receptor for S100A9. CAP37 and one peptide partially activated TLR4. The other three peptides did not activate TLR4. Finally, we found that CAP37 and all four peptides could inhibit the activation of TLR4 by S100A9. CONCLUSIONS: This study identifies a mechanism of action for CAP37 and derived antimicrobial peptides that may restrain inflammatory responses to corneal injury and favor corneal re-epithelialization.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Kasus-Jacobi A, Land CA, Stock AJ, et al. Antimicrobial Peptides Derived from the Immune Defense Protein CAP37 Inhibit TLR4 Activation by S100A9. Invest Ophthalmol Vis Sci. 2020. PMID: 32298435. doi:10.1167/iovs.61.4.16

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。